51 results about "Heme oxygenase" patented technology

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of soluble CD44 antigen, Angiopoietin-1, soluble Angiopoietin-1 receptor, C—X—C chemokine motif 5, soluble Endoglin, soluble Tumor-associated calcium signal transducer 1, Erythropoietin, soluble Fractalkine, Heme oxygenase 1, soluble Interleukin-1 receptor type II, soluble Interleukin-6 receptor subunit-alpha, Lymphotactin, Lymphotoxin-alpha, Stromelysin-1, C—C motif chemokine 22, C—C motif chemokine 5, and Thrombospondin-1 as diagnostic and prognostic biomarkers in renal injuries.

The invention provides a transgenic animal carrying two transgenes, one encoding a human decay accelerating factor (hDAF) and the other encoding a human heme oxygenase-1 (hHO)-1, which are useful for providing cells, tissues or organs therefrom for xenotransplantation.

Medicinal compositions for treating or preventing diabetes, rheumatoid, diseases wherein inflammation should be inhibited, diseases wherein alpha-glycosidase should be inhibited, diseases wherein the synthesis of prostaglandin should be inhibited, diseases wherein endotoxin shock should be inhibited, diseases wherein the production of interleukin should be inhibited, diseases wherein the production of heme oxygenase should be induced, and diseases wherein the production of tumor necrosis factor or carcinogenesis should be inhibited, which contain as the active ingredient at least one compound selected from the group consisting of 3,6-anhydrogalactopyranose represented by formula (I), its aldehyde, its hydrate and 2-O-methylated derivatives and 2-O-sulfated derivatives thereof.

Inhibitors of microbial heme oxygenase and their use for treatment of microbial infections and bioremediation. The inhibitors of microbial heme oxygenase are useful against a new class of antimicrobial agents to target infections that are persistently difficult to combat with the current spectrum of antimicrobial agents. Screening methods for selecting inhibitors of microbial heme oxygenase.

Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating inflammation are provided. The substituted fused imidazole derivatives may control the activity or the amount or both the activity and the amount of heme-oxygenase.

The invention provides a transgenic animal carrying two transgenes, one encoding a human decay accelerating factor (hDAF) and the other encoding a human heme oxygenase-1 (hHO)-1, which are useful for providing cells, tissues or organs therefrom for xenotransplantation.

Anticancer agents which contain as the active ingredient, a heme oxygenase inhibitory metalloporphyrin derivatives which are conjugated with amphipathic or water-soluble polymers (in particular, Zn-protoporphyrin (ZnPP) conjugated with polyethylene glycol). Because of being conjugated to amphipathic or water-soluble polymers, such as polyethylene glycol, the active ingredient can be administered by intravenous injection and can exert a remarkable anticancer effect owing to tumor selective delivery.

The invention relates to the field of biotechnology and particularly relates to a method for establishing an Alzheimer disease pathologic model based on the transgenic technology. In the invention, the Alzheimer disease pathologic model is established by generally over-expressing an HO-1 (heme oxygenase-1) gene in a mouse by using the transgenic technology. The transgenic mouse automatically forms the Alzheimer disease tau pathology, which is an ideal animal model for researching the generation mechanism of neurofibrillary tangles as a typical pathologic symbol of Alzheimer disease.

Anticancer agents which contain as the active ingredient, a heme oxygenase inhibitory metalloporphyrin derivatives which are conjugated with amphipathic or water-soluble polymers (in particular, Zn-protoporphyrin (ZnPP) conjugated with polyethylene glycol). Because of being conjugated to amphipathic or water-soluble polymers, such as polyethylene glycol, the active ingredient can be administered by intravenous injection and can exert a remarkable anticancer effect owing to tumor selective delivery.

The invention relates to a process for separation and purification of gene recombinant protein heme oxygenase, which comprises subjecting the expression recombination protoheme oxygenase-1 fermentation liquor to centrifugal collection of cells, ultrasonic wave fragmenting, expanded-bed ion exchange chromatography and gel filtration chromatography for purification preparation. Compared with the existing separation process, provided method has the advantages of substantially reduced time of separation process and increased yield of recombination human heme oxygenase-1.

The invention relates to a bismuth sulfide-zinc protoporphyrin composite material with a tumor photodynamic therapy (PDT) property under excitation of near-infrared light as well as a preparation method and application and belongs to the field of composite materials, aiming at solving the problem that the PDT efficiency is relatively low, caused by photoelectron-hole compounding in a photodynamictherapy process of bismuth sulfide and an anti-oxidization stress capability of heme oxygenase (HO-1) in cells. The composite material is the bismuth sulfide-zinc protoporphyrin composite material which is obtained by synthesizing a polyN-isopropylacrylamide-acrylamide copolymer modified bismuth sulfide nano-material and then carrying out condensation reaction of carboxyl and amino. The prepared composite material has the effect of enhancing the photodynamic therapy efficiency through two ways of inhibiting the activity of the heme oxygenase and promoting electron-hole separation; meanwhile, the material provided by the invention has good biocompatibility, light stability, CT (Computed Tomography) imaging capability and enhanced PDT efficiency; a thought is provided for designing a novel nano diagnosis and treatment integrated system and the material has important meaning on early-stage diagnosis and treatment of cancers.

A supplement including a blend of turmeric, quercetin and rosemary, or holy basil, wasabi, and broccoli seed extract which are present in a balanced and predetermined ratio, and which stimulate the Antioxidant Response Element (ARE), Quinone Reductase, and / or induce related gene expression, for example, heme oxygenase-1 (HMOX-1) expression. The blend of ingredients can be formed as or in a dietary supplement adapted for administration to a subject. The dietary supplement can be formulated so that the turmeric, quercetin and rosemary are present in a predetermined ratio of 1:3:5, or holy basil, wasabi, and broccoli seed extract in a predetermined ratio of 1:1:0.2. Additional ingredients can be included in the supplement. The supplement can synergistically affect natural antioxidant response pathways within cells of a subject to whom the supplement is administered. A related method of use is also provided.

The invention discloses application of an HO (Heme Oxygenase)-1 inhibitor in preparing medicine for treating cardiotoxicity induced by anti-cancer medicine-doxorubicin. The HO-1 inhibitor is zinc protoporphyrin. According to the application disclosed by the invention, basis is provided for new drug research and development and innovative therapy.

The invention provides application of a fumarate compound to the preparation of an adjusting medicine for a macrophage subpopulation. Discovered experimentally, the fumarate compound can be used for decreasing the level of a pro-inflammatory M1-type macrophage of a mammal, and meanwhile, can be used for raising the level of an anti-inflammatory M2-type macrophage, and such a change is clear to realize by promoting the differentiation of the M1-type macrophage to the M2-type macrophage. On this basis, the fumarate compound is discovered to be capable of increasing the expression quantities of a nuclear transcription factor 2 (Nrf2) of an anti-oxidation transcription factor and a target gene heme oxygenase 1 (HO-1) thereof, so as to promote the differentiation of the M1-type macrophage to the M2-type macrophage, and therefore, the mechanism of the action of the fumarate compound in the adjustment of the macrophage subpopulation is clear. Based on the above newly discovered new properties, the new purpose for preparing the adjusting medicine for the macrophage subpopulation by utilizing the fumarate compound is determined by the application of the fumarate compound to the preparation of the adjusting medicine for the macrophage subpopulation, so that a new treatment approach is provided for multiple diseases which use the maladjustment of the macrophage subpopulation as an effect.

The invention provides a nanogel drug carrier for targeted delivery and consumption of a large amount of H2O2 and release of CO at the same time, and a preparation method and application thereof. Thenanogel drug carrier is a dendritic polypeptide nanogel drug carrier. The drug carrier comprises dendritic polypeptide nanogel as a carrier, and a carbon monoxide release molecules CORM401 loaded in an internal cavity of the dendritic polypeptide nanogel, and also comprises hyaluronic acid which is modified by folic acid and coats the surface of the dendritic polypeptide nanogel. A multifunctionalanti-inflammatory drug (CPHs) is prepared on the basis of the nanogel drug carrier disclosed by the invention. The drug carrier can enter activated macrophages in a HA-FA targeting manner, and rapidly release a large amount of CO is by consuming excessive H2O2. The generated CO not only can effectively inhibit cell proliferation, but also can obviously inhibit secretion of inflammatory factors byinducing activation (HO-1) of heme oxygenase and down-regulating expression of p38MAPK, NF-kB (p50 / p65) and TLR-2. The CPHs can consume a large amount of ROS at the osteoarthritis joint part, and effectively inhibit degradation of articular cartilage and extracellular matrix.

The present invention relates to a method for the prevention of allograft rejection in clinical transplantation. Specifically, the method of the present invention relates to the prevention of transplant arteriosclerosis and interstitial fibrosis by stable and long-term expression of HO-1 in grafts. The present invention represents a novel therapeutic approach to prevent allograft rejection in clinical transplantation.

A method of treating or inhibiting progress of dementia and / or macular degeneration in a mammal involves administering compositions containing siRNA to heme oxygenase-1 (HO-1) or heme oxygenase-2 (HO-2), a matrix metalloproteinase (MMP) inhibitor, a caspase inhibitor, or a metalloporphyrin in a manner that permits access to brain sites and / or the macula of the patient.

The invention relates to an improved method for predicting the onset of, diagnosing, prognosticating and / or treating dementing diseases. The method comprises determining the level of heme oxygenase-1 suppressor (HOS) activity and / or factor in tissue or body fluid obtained from a patient, and comparing said level with the corresponding level of HOS activity and / or factor in corresponding tissue or body fluid obtained from at least one control person. The tissue or body fluid is suitably blood, plasma, lymphocytes, cerebrospinal fluid, urine, saliva, epithelia or fibroblasts. The method is useful where the dementing disease is any of Alzheimer Disease, Age-Associated Cognitive Decline, Mild Cognitive Impairment, Parkinson disease with dementia, Progressive Supranuclear Palsy, Vascular (i.e. multi-infarct) Dementia, Lewy Body Dementia, Huntington's Disease, Down's syndrome, normal pressure hydrocephalus, corticobasal ganglionic degeneration, multisystem atrophy, head trauma, neurosyphilis, Creutzfeld-Jacob disease and other prion diseases, HIV and other encephalitides, and metabolic disorders such as hypothyroidism and vitamin B12 deficiency. The method may also prove useful in differentiating the“pseudodementia” of depression from Alzheimer disease.

The invention provides an application of a DNA tetrahedron in the aspect of improving anti-aging process of cells. The DNA tetrahedron is synthesized from four DNA single chains in a self-assembling manner, wherein the sequences of the four single chains are represented as the SEQ ID No.1-4. The anti-aging process of cells includes anti-inflammation and anti-oxidizing processes, wherein the anti-inflammation effect, improved by the DNA tetrahedron, of the cells is achieved by reducing release of inflammatory cytokines and inhibiting expression quantities of iNOS gene and iNOS protein; the anti-oxidizing of the cells is achieved by inhibiting the phosphorylation of proteins ERK1 / 2, P38 and JNK at the downstream of MAPK / ERK signal channel, and improving the expression quantity of inducing heme oxygenase-1. The DNA tetrahedron has excellent bioavailability and biocompatibility, has anti-inflammation and anti-oxidizing functions and further delays senility of cells.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of soluble CD44 antigen, Angiopoietin-1, soluble Angiopoietin-1 receptor, C-X-C chemokine motif 5, soluble Endoglin, soluble Tumor-associated calcium signal transducer 1, Erythropoietin, soluble Fractalkine, Heme oxygenase 1, soluble Interleukin-1 receptor type II, soluble Interleukin-6 receptor subunit-alpha, Lymphotactin, Lymphotoxin-alpha, Stromelysin-1, C-C motif chemokine 22, C-C motif chemokine 5, and Thrombospondin-1 as diagnostic and prognostic biomarkers in renal injuries.

The invention discloses a medicine for treating lipopolysaccharide / D-aminogalactose (LPS / GalN) induced liver injury. The medicine for treating lipopolysaccharide / D-aminogalactose (LPS / GalN) induced liver injury is forsythiaside A. The forsythiaside A is capable of alleviating liver pathological injury induced by lipopolysaccharide / D-aminogalactose (LPS / GalN), reducing content of malonaldehyde (MDA) and serum ALT (Alanine Aminotransferase) and AST (Aspartate Amino Transferase) levels. In addition, the forsythiaside A is capable of inhibiting NF-chiB activation, serum TNF-alpha and liver TNF-alpha levels caused by LPS / GalN. In addition, the forsythiaside A is capable of increasing expression of Nrf2 and haem oxygenase 1. Results show that the protection function of the forsythiaside A on LPS / GalN induced liver injury is achieved by activating Nrf2 and inhibiting NF-chiB activation.

The present invention relates to hybrid fumarate-CO-releasing molecules capable of increasing heme oxygenase-1 (HO-1) activity and HO-1 protein expression and simultaneously releasing CO, their synthesis and their use in therapeutic applications, in particular their use in the treatment of inflammatory or cardiovascular diseases.

Substituted pyridine derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted pyridine derivative, and methods of use in treating inflammation are provided. The substituted pyridine derivatives may control of the activity or the amount or both the activity and the amount of heme-oxygenase.

The invention belongs to the field of molecular biological diagnosis and treatment of radiation-induced lung injury, and particularly relates to application of heme oxygenase-1 in diagnosis and treatment of radiation-induced lung injury. It is found that serious radiation-induced lung injury is caused by insufficient HO-1 content, so that for a patient subjected to large-dose X-ray radiation therapy, if HO-1 in blood is reduced, radiation-induced lung injury is caused. A drug such as Hemin for enhancing the expression and function of HO-1 can be used as a new method for treating radiation-induced lung injury.

The invention provides a nanogel drug carrier for targeted delivery and consumption of a large amount of H2O2 and release of CO at the same time, and a preparation method and application thereof. Thenanogel drug carrier is a dendritic polypeptide nanogel drug carrier. The drug carrier comprises dendritic polypeptide nanogel as a carrier, and a carbon monoxide release molecules CORM401 loaded in an internal cavity of the dendritic polypeptide nanogel, and also comprises hyaluronic acid which is modified by folic acid and coats the surface of the dendritic polypeptide nanogel. A multifunctionalanti-inflammatory drug (CPHs) is prepared on the basis of the nanogel drug carrier disclosed by the invention. The drug carrier can enter activated macrophages in a HA-FA targeting manner, and rapidly release a large amount of CO is by consuming excessive H2O2. The generated CO not only can effectively inhibit cell proliferation, but also can obviously inhibit secretion of inflammatory factors byinducing activation (HO-1) of heme oxygenase and down-regulating expression of p38MAPK, NF-kB (p50 / p65) and TLR-2. The CPHs can consume a large amount of ROS at the osteoarthritis joint part, and effectively inhibit degradation of articular cartilage and extracellular matrix.

The invention relates to creation and application of an anti-hepatitis B model based on host cell targets. Heme oxygenase-1 is adopted as a target, human heme oxygenase-1 genes and hepatitis B virus protein genes are transferred into liver cells through carriers for expression, and simultaneous targeting of heme oxygenase-1 and a creation program and evaluation method of an anti-hepatitis B virusmedicine evaluation model based on interaction between heme oxygenase-1 and hepatitis B virus protein are achieved. Especially, the host cell components are adopted as the targets, the anti-hepatitisB in-vitro model with high specificity and excellent pertinence is generated, and the application of the model in research on hepatitis pathogenesis mechanisms, drug therapies and research and development of innovative drugs is achieved.

A supplement including a blend of turmeric, quercetin and rosemary, or holy basil, wasabi, and broccoli seed extract which are present in a balanced and predetermined ratio, and which stimulate the Antioxidant Response Element (ARE), Quinone Reductase, and / or induce related gene expression, for example, heme oxygenase-1 (HMOX-1) expression. The blend of ingredients can be formed as or in a dietary supplement adapted for administration to a subject. The dietary supplement can be formulated so that the turmeric, quercetin and rosemary are present in a predetermined ratio of 1:3:5, or holy basil, wasabi, and broccoli seed extract in a predetermined ratio of 1:1:0.2. Additional ingredients can be included in the supplement. The supplement can synergistically affect natural antioxidant response pathways within cells of a subject to whom the supplement is administered. A related method of use is also provided.

The invention relates to application of heme oxygenase-2 in preparing preparations inhibiting organ transplantation immune rejection, and discloses application of heme oxygenase-2 and genes thereof in preparing preparations inhibiting organ transplantation immune rejection. The preparation can be used for inhibiting organ transplantation immune rejection and can increase the organ transplantation survival rate, and an effective method is provided for treating chronic end-stage diseases of the liver, the kidneys, the heart and the like.

Inhibitors of microbial heme oxygenase and their use for treatment of microbial infections and bioremediation. The inhibitors of microbial heme oxygenase are useful against a new class of antimicrobial agents to target infections that are persistently difficult to combat with the current spectrum of antimicrobial agents. Screening methods for selecting inhibitors of microbial heme oxygenase.